📞 
— free, 24/7
— free, 24/7 — free, 24/7| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 5mg | 360 pills | £0.73 | £348.84 £261.63 Best Price Popular | |
| 5mg | 240 pills | £0.76 | £242.99 £182.24 | |
| 5mg | 180 pills | £0.79 | £190.81 £143.11 | |
| 5mg | 120 pills | £0.89 | £143.10 £107.33 | |
| 5mg | 90 pills | £0.97 | £116.27 £87.20 | |
| 5mg | 60 pills | £1.10 | £87.94 £65.96 | |
| 5mg | 30 pills | £1.34 | £53.65 £40.24 | |
| 10mg | 240 pills | £1.04 | £332.44 £249.33 | |
| 10mg | 120 pills | £1.05 | £168.45 £126.34 | |
| 10mg | 90 pills | £1.11 | £132.67 £99.50 | |
| 10mg | 60 pills | £1.16 | £92.42 £69.31 | |
| 10mg | 30 pills | £1.24 | £49.18 £36.89 |
Disclaimer: This information is intended for adults and should not replace professional medical advice. Consult a pharmacist or clinician for personalised guidance before using Zelapar.
Zelapar (selegiline) is a monoamine oxidase-B (MAO-B) inhibitor used to treat Parkinson’s disease by increasing dopamine levels in the brain. This mechanism helps to improve motor symptoms such as slowness, stiffness and tremor in many people affected by the condition.
The medicine is supplied as an orally disintegrating tablet (ODT), designed to dissolve on the tongue without the need to swallow a tablet whole. The MAO-B selective action at therapeutic doses reduces the breakdown of dopamine, supporting better control of movement for some patients.
Selegiline belongs to the class of MAO inhibitors, but the selective targeting of MAO-B at usual doses lowers, though does not eliminate, the risk of interactions with certain foods and medicines. The exact regimen and duration of therapy will be determined by a clinician based on individual needs and response to treatment.
The exact product name and formulation may differ by country; in the United Kingdom, Zelapar is supplied as an oral disintegrating tablet for prescription use. Availability and prescribing rules depend on local regulations. Check the official patient information leaflet or discuss with a healthcare professional if any doubt exists.
The primary therapeutic purpose is to improve motor symptoms in adults with Parkinson’s disease. Zelapar may help reduce motor fluctuations and improve daily functioning in some individuals.
It can be used as an initial therapy in early Parkinson’s disease or introduced as an adjunct to other Parkinson’s medicines in established disease. The exact role of Zelapar is determined by the treating clinician, based on symptom profile and other treatments being used.
Performance in non-mymmetric motor symptoms, rigidity, and bradykinesia varies between people. Zelapar is not a cure for Parkinson’s disease and does not halt disease progression. It is not indicated for conditions outside Parkinson’s disease unless specified by a clinician.
When used alongside other drugs, potential interactions may influence effectiveness or safety. A pharmacist or clinician should review the entire medication list, including over‑the‑counter products and herbal supplements, before starting therapy. If uncertainty arises, check the official leaflet or seek professional advice.
Starting therapy involves careful preparation and a plan discussed with a clinician or pharmacist. The following steps describe a typical approach, but dosing and monitoring are individually tailored and must be prescribed by a healthcare professional.
Initial assessment is completed to identify potential drug interactions, contraindications, and any risk factors. A medical history is reviewed, including other conditions such as hypertension, liver function issues, and current medications.
Before the first dose, information about how to use Zelapar correctly is reviewed. The oral disintegrating tablet is placed on the tongue and allowed to dissolve; no swallowing of the tablet whole is required. Once dissolved, it may be followed by a small amount of water if desired, but the tablet should not be chewed. If there is any difficulty with swallowing or with the tablet form, alternatives or adjustments will be considered by the clinician.
If a dose should be missed or if an unexpected reaction occurs, instructions are provided for corrective steps. Patients are advised to keep a record of any adverse effects, changes in symptoms, or concerns to support ongoing clinical review. It is important to obtain and keep the current information leaflet provided with Zelapar for reference during follow‑up visits.
Ensure the medicine being taken matches the prescription label and the patient information leaflet. The tablet dissolves on the tongue and should not be chewed or swallowed whole. Confirm any changes in brand, strength, or formulation with a pharmacist before use.
Check the appearance of the tablet and ensure the packaging is intact. If the product seems damaged or different from the one described by the prescribing clinician, do not use it until a pharmacist clarifies the situation.
Note any pharmacy-specific instructions, including whether the medication should be taken at a particular time of day. Follow the clinician’s exact instructions unless advised otherwise by a healthcare professional.
Review all medicines currently used, including over‑the‑counter products and herbal supplements. Some substances can interact with MAO-B inhibitors and may require dose adjustments or alternative therapies. A clinician or pharmacist can assess compatibility and safety.
Known contraindications and precautions will be discussed. If a history of severe liver or kidney disease, uncontrolled blood pressure, or hunting for any other condition exists, it should be disclosed to the clinician before starting Zelapar.
Discuss any planned procedures, anesthesia, or the use of other medicines such as antidepressants, pain relievers or cough medicines, as these can influence safety. If uncertain about a potential interaction, seek professional guidance rather than guessing.
A tailored plan for initiation, follow‑up appointments, and symptom monitoring will be arranged. The clinician may adjust additional Parkinson’s medicines when introducing Zelapar to avoid excessive dopaminergic effects or early adverse reactions.
Information about what to expect in the early stages of therapy will be provided. Some patients may notice gradual improvements in movement over weeks, while others may require longer to respond. Regular contact with a healthcare professional supports timely identification of issues or need for dose adjustments.
Practical considerations for therapy, including how to handle missed doses and what to do during travel or disruptions to routine, will be outlined. The goal is to support consistent daily use and safe management of potential interactions.
Plan for possible side effects and how to manage them. Some people may experience light-headedness, sleep disturbances, or dry mouth as the body adjusts to the new therapy. If troubling symptoms occur, a clinician should be consulted for advice on management or dose adjustment.
A strategy for daytime activities and driving safety will be discussed if dizziness or sleepiness occurs. If dizziness, fainting, or confusion develops, seek medical evaluation promptly.
Written guidance and contact information for the treating team should be readily available. The patient information leaflets provided with Zelapar contain additional safety details to review during the course of therapy.
Daily administration should be performed consistently, following the prescriber’s instructions. The timing in each day supports steady levels of the medicine in the body and the best chance of symptom control.
The oral disintegrating tablet is intended to dissolve on the tongue. Do not swallow the tablet whole or with water unless advised by a clinician after dissolution. Hydration and proper oral hygiene should be maintained as part of routine care.
Information about meals and timing in relation to Zelapar may be provided. The medicine can be taken with or without food, but a consistent routine reduces the risk of missed doses and variable absorption. Any dietary restrictions or considerations will be explained by the clinician.
A plan for missed doses is provided. If a dose is skipped, instructions will indicate whether to take it as soon as remembered or to skip and resume the regular schedule. Do not double the dose to compensate for a missed one unless specifically advised by a clinician.
Take Zelapar at the same time each day if possible. Establishing a routine supports adherence and helps maintain steady medication levels. A daily reminder or medication organiser can be useful for some patients.
Do not adjust the timing or frequency of doses without consulting a clinician. Changes can affect the effectiveness and safety of therapy and may necessitate medical review.
Keep the treatment plan visible at home, with any notes about timing, missed doses, or side effects accessible for reference during follow-up appointments.
The disintegrating tablet dissolves on the tongue and should not be swallowed whole. It can be taken with or without food, but a consistent pattern is beneficial for routine management. If a specific instruction was given, follow that guidance.
Place the tablet on the tongue and allow it to dissolve completely. There is no requirement to swallow with water, though small sips of water can be used after dissolution if desired. Do not chew or crush the tablet.
If difficulty occurs with dissolution, or if swallowing issues are present, discuss alternatives with a clinician. Do not attempt to alter the tablet form independently.
If a dose is missed, follow the prescribed plan provided at initiation. In some cases, the dose may be skipped and the regular schedule resumed the next day. Doubling doses is not advised unless explicitly directed by a clinician.
Significant time between doses may reduce symptom control. If the routine is disrupted for an extended period, contact a clinician for guidance before resuming treatment. Do not restart at a higher dose without professional advice.
For changes in daily routine such as travel, the clinician can offer practical modifications to maintain adherence and safety. Written travel guidance may be provided as part of the care plan.
Avoid making changes to other medicines during the first weeks of Zelapar use without medical guidance. Some medications have interactions that can affect safety or effectiveness. If new medicines are required, notify the clinician promptly.
Monitor daily activities for any dizziness, sleepiness, or confusion. If such symptoms occur, avoid driving or operating heavy machinery until clarified by a professional. Seek medical advice if symptoms persist or worsen.
Maintain a record of symptom changes and any adverse effects. This information supports ongoing dose adjustments and safety reviews during follow-up visits.
Improvements in Parkinson’s motor symptoms often take time to become noticeable. Some individuals may observe gradual benefit over several weeks, while others may require longer to see a meaningful change. The trajectory varies between people.
The first weeks may include adjustments as the body responds to the medicine and any interactions with other therapies are clarified. A clinician may modify the broader treatment plan to optimise benefit while minimising adverse effects.
Common early experiences include mild dizziness, headaches, or dry mouth. Sleep patterns, mood, and appetite can also shift during the initial period. If any symptom raises concern, seek clinical advice promptly.
It is important to report persistent or worsening symptoms, unexpected changes in blood pressure, or signs of serotonin syndrome (such as altered mental status, rapid heart rate, or fever). Seek urgent medical help if severe symptoms develop.
Safety monitoring is a routine part of Zelapar therapy. Regular reviews assess symptoms, side effects, and interactions with other medicines. Any new health issue or medication change should be discussed with the clinician promptly.
Key red flags include severe headache with neck stiffness, chest pain, shortness of breath, fainting, or severe mood changes. Seek immediate medical evaluation if these occur.
Serious reactions may include signs of serotonin syndrome or hypertensive crisis, though these are rare with MAO-B inhibitors at approved doses. If unusual or severe symptoms arise, contact a healthcare professional without delay.
If pregnancy or breastfeeding is considered or suspected, medical advice should be sought. The clinician will discuss potential risks and alternative options. Do not discontinue therapy without professional guidance.
Store Zelapar at room temperature in a dry place away from direct heat or sunlight. Keep the original packaging until used to protect tablets from moisture and damage. Do not use beyond the expiry date printed on the packaging.
Keep Zelapar out of reach of children and pets. Do not transfer tablets to other containers. If any packaging is damaged or the tablet appears compromised, contact a pharmacist for guidance before use.
Open pills should be discarded as instructed by the leaflet or pharmacist if the product has been opened for a long period or if there are changes in appearance, odour, or texture. Proper disposal guidelines help prevent accidental ingestion by others.
Portable storage for travel should maintain protection from heat and moisture. When travelling, carry Zelapar in its original packaging and carry essential information about the medication for reference in case of medical emergencies.
The information above is not exhaustive. If there is any uncertainty about safety, check the official patient information leaflet or consult a pharmacist or clinician for personalised advice. Do not make changes to treatment without professional guidance.
When undergoing treatment with Zelapar, considerations include interactions with foods, medicines, and activities that may be influenced by changes in dopamine levels. A careful approach helps optimise benefit while minimising adverse effects.
In case of surgery or dental procedures, inform the healthcare team about Zelapar in advance. Some anaesthetic agents or pain medications can interact with MAO-B inhibitors, requiring adjustments or monitoring.
Travel plans, seasonal changes, or new health events should be discussed with the treating clinician. A clear action plan supports continued symptom control during disruptions to routine care.
There is no suggestion that Zelapar should be used in place of non-pharmacological therapies unless advised by a clinician. Ongoing physical therapy, exercise, and lifestyle modifications remain important elements of Parkinson’s disease management.
Use during pregnancy or breastfeeding is generally approached with caution. The clinician will assess potential risks and benefits and provide guidance based on individual circumstances. If pregnancy is planned or suspected, seek medical advice promptly.
No. Zelapar is an orally disintegrating tablet designed to dissolve on the tongue. It should not be crushed or swallowed whole unless instructed by a clinician. Proper use supports expected absorption and effect.
Alcohol can interact with medicines that affect the brain and blood pressure. It is advised to limit or avoid alcohol while using Zelapar, and to discuss any planned drinking with a clinician, especially during dose adjustments or if any dizziness occurs.
Decision should be based on personal experience. If dizziness, drowsiness, or impaired alertness occurs, avoid driving or operating heavy machinery until it is clear that activities are safe. Seek advice if symptoms persist.
Do not double the dose to make up for a missed one unless explicitly advised by the clinician. The next dose should be taken as scheduled, and guidance may be provided for missed doses during initiation or travel.
Improvements in motor symptoms may take several weeks and can vary between individuals. Some patients notice gradual benefit over time, while others require additional time or adjustments to their regimen.
Switching should be done under professional supervision. A clinician may adjust the treatment plan to maintain symptom control while reducing the risk of adverse effects. Self-initiated changes are not advised.
Many over‑the‑counter medicines can interact with MAO inhibitors. Prior to taking any non-prescription products, including cough medicines, decongestants, or herbal supplements, consult a pharmacist or clinician to confirm safety.
Major dietary restrictions are less common with selective MAO-B inhibitors at standard doses, but some clinicians advise avoiding foods high in tyramine if advised. Always follow the guidance given by the clinician and promptly report any unusual blood pressure symptoms.
Switching is possible under medical supervision, with consideration given to the timing and interaction with existing therapies. A staged plan may be used to minimise adverse effects and maintain symptom control.
Yes. Inform the dental or surgical team about Zelapar prior to procedures. Certain anaesthetics and perioperative medications can interact with MAO inhibitors, requiring monitoring or adjustments.
Use in younger individuals is uncommon and requires specialist assessment. Therapy is generally directed at adults with Parkinson’s disease, with careful consideration of risks and benefits if paediatric use is contemplated.
Discontinuation should be guided by a clinician. Stopping suddenly can cause withdrawal effects or return of symptoms. A clinician may propose a gradual reduction over time if stopping is appropriate.
New or worsening symptoms warrant medical review. This may indicate a need for dose adjustment, evaluation of interactions, or consideration of alternative therapies. Prompt reporting supports safer management.
Such symptoms may indicate a serious reaction and require immediate medical evaluation. Seek urgent medical help if these occur, particularly if accompanied by agitation, rapid heart rate, or fluctuating blood pressure.
Medicines used for dental relief can interact with MAO inhibitors. Inform the dental care team about Zelapar to ensure safe choices for analgesia and any anaesthetic planning. Coordination helps prevent adverse reactions.
Maximum benefit may take several weeks, and some patients notice ongoing improvement over months. Ongoing clinical review supports adjustment of therapy to optimise symptom control.
Some herbal products and supplements can interact with MAO inhibitors. Before starting any new remedy, discuss with a clinician or pharmacist to confirm safety and compatibility.
Standard storage conditions are typically at room temperature, away from heat and moisture. Specific packaging and shelf-life information is provided with the product and should be followed. If there is any uncertainty, consult the pharmacist for guidance.
14–21 days. Free from £149.08 .
5–9 days. £22.36
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
